SiBone (NASDAQ:SIBN) Stock: Insider Laura Francis Sells 75,000 Shares

SiBone (NASDAQ:SIBN) CEO Laura Francis sold 75,000 shares of the business’s stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $25.30, for a total value of $1,897,500.00. Following the completion of the transaction, the chief executive officer directly owned 304,256 shares in the company, valued at $7,697,676.80. This represents a 19.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Laura Francis also recently made the following trade(s):

• On Monday, October 12th, Laura Francis sold 38,006 shares of SiBone stock. The stock was sold at an average price of $20.05, for a total value of $762,020.30.
• On Monday, August 24th, Laura Francis sold 25,972 shares of SiBone stock. The shares were sold at an average price of $20.12, for a total transaction of $522,556.64.
• On Friday, August 21st, Laura Francis sold 3,923 shares of SiBone stock. The shares were sold at an average price of $20.02, for a total transaction of $78,538.46.
• On Thursday, August 20th, Laura Francis sold 51,884 shares of SiBone stock. The shares were sold at an average price of $19.46, for a total transaction of $1,009,662.64.

SiBone Stock Down 0.1%

Shares of NASDAQ SIBN opened at $24.24 on Friday. The firm has a market cap of $1.09 billion, a PE ratio of -78.19 and a beta of 0.64. SiBone has a 12-month low of $11.48 and a 12-month high of $25.92. The company’s fifty day simple moving average is $19.81 and its 200 day simple moving average is $16.59. The company has a quick ratio of 7.55, a current ratio of 7.58 and a debt-to-equity ratio of 0.19.

SiBone (NASDAQ:SIBN) last posted its quarterly earnings results on Monday, November 2nd. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.05. SiBone had a negative net margin of 6.20% and a negative return on equity of 7.57%. The firm had revenue of $55.70 million during the quarter, compared to the consensus estimate of $55.31 million. As a group, sell-side analysts forecast that SiBone will post -0.34 earnings per share for the current fiscal year.

Trending Headlines about SiBone

Here are the key news stories impacting SiBone this week:

• Positive Sentiment: Quarterly results beat expectations and lifted shares. Si-Bone reported a third-quarter loss of $0.08 per share, narrower than the $0.13 loss analysts expected, while revenue of $55.7 million modestly exceeded estimates. The results were followed by a reported 8.7% stock jump. Article on SIBN’s post-earnings gain
• Positive Sentiment: Analyst support helped drive the stock to a 52-week high. TD Cowen raised its price target to $23 from $20, and UBS raised its target to $26 from $25; both maintained Buy ratings. SIBN reached a 52-week high amid the favorable coverage and earnings momentum. Article on SIBN’s 52-week high and analyst upgrade TD Cowen price-target article UBS price-target article
• Neutral Sentiment: Full-year revenue guidance was reaffirmed. Si-Bone’s 2026 revenue outlook of $231 million to $233 million was broadly in line with analyst expectations, offering limited new information for investors. Si-Bone Q3 results and guidance
• Negative Sentiment: Multiple insiders sold shares. CEO Laura Francis sold 75,000 shares, SVP Michael Pisetsky sold 36,241, Anshul Maheshwari sold 3,247, and director Jeffrey Dunn sold 20,000. The sales may weigh on sentiment, although each retained shares after the transactions. CEO sale filing SVP sale filing Maheshwari sale filing Dunn sale filing

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. UBS Group upped their price target on SiBone from $25.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, November 3rd. Weiss Ratings raised SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 20th. Citigroup restated a “market outperform” rating on shares of SiBone in a report on Tuesday. Truist Financial boosted their price objective on SiBone from $23.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday, October 14th. Finally, Needham & Company LLC lowered their target price on SiBone from $27.00 to $26.00 and set a “buy” rating on the stock in a research report on Tuesday. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $25.00.

Institutional Investors Weigh In On SiBone

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Versant Capital Management Inc boosted its stake in shares of SiBone by 102.9% in the 2nd quarter. Versant Capital Management Inc now owns 1,749 shares of the company’s stock worth $29,000 after buying an additional 887 shares during the last quarter. State of Wyoming grew its holdings in shares of SiBone by 70.8% in the first quarter. State of Wyoming now owns 10,832 shares of the company’s stock valued at $137,000 after acquiring an additional 4,490 shares in the last quarter. Inceptionr LLC bought a new position in shares of SiBone in the first quarter valued at approximately $156,000. ADAR1 Capital Management LLC bought a new position in shares of SiBone in the first quarter valued at approximately $159,000. Finally, Elevation Point Wealth Partners LLC purchased a new stake in shares of SiBone during the first quarter valued at approximately $204,000. Hedge funds and other institutional investors own 98.11% of the company’s stock.

About SiBone

SI-BONE, Inc (NASDAQ: SIBN) is a medical device company focused on diagnosing and treating disorders of the sacroiliac joint, which connects the spine to the pelvis. The company develops minimally invasive surgical solutions intended to stabilize the sacroiliac joint and address sacroiliac joint dysfunction and related conditions.

Its product portfolio is centered on the iFuse Implant System, a family of triangular implants designed to be placed across the sacroiliac joint. SI-BONE also offers products such as iFuse-TORQ, a threaded implant system, and iFuse Bedrock Granite, which is designed for sacroiliac joint fusion and pelvic fixation as part of certain spinal procedures.